Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
Med Res Rev. 2019 Jan;39(1):328-348. doi: 10.1002/med.21515. Epub 2018 May 30.
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism-related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health-care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets.
非酒精性脂肪性肝病（NAFLD）正在迅速成为全球最常见的肝脏疾病。NAFLD 患者发生进行性肝病和代谢相关合并症的频率较高，这是由于对该病的认识不足和监测不力，以及缺乏批准和有效的治疗方法所致。管理 NAFLD 的并发症已经开始给医疗保健系统带来巨大负担。虽然正在努力寻找有效的治疗方法，但缺乏能够代表人类疾病的生物学和结果的经过验证的临床前 NAFLD 模型仍然是一个主要障碍。这篇综述总结了该病的特征和流行情况，以及我们对其发病机制和潜在治疗靶点的理解现状。
